Gilder Gagnon Howe & Co’s Charles River Laboratories CRL Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,824	Closed	-$8.22M	–	308
2021 Q4	$8.22M	Sell	21,824 -1,075	-5%	-$418K	0.05%	188
2021 Q3	$9.45M	Sell	22,899 -5	-0%	-$2.08K	0.05%	207
2021 Q2	$8.47M	Sell	22,904 -2,447	-10%	-$817K	0.04%	223
2021 Q1	$7.35M	Buy	25,351 +48	+0.2%	+$13.3K	0.04%	219
2020 Q4	$6.32M	Buy	25,303 +230	+0.9%	+$54.8K	0.03%	201
2020 Q3	$5.68M	Sell	25,073 -159	-0.6%	-$33K	0.04%	188
2020 Q2	$4.4M	Buy	+25,232	New	+$4.03M	0.03%	182

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Gilder Gagnon Howe & Co's CRL Position: Q1 2022 in Review

Gilder Gagnon Howe & Co sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 21,824 shares — an estimated $8.22M sold.

Gilder Gagnon Howe & Co first reported a position in CRL in Q2 2020 and held it in 7 quarters. The position peaked at $9.45M in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Gilder Gagnon Howe & Co reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 21,824 Charles River Laboratories shares in Q1 2022, an estimated $8.22M.
Gilder Gagnon Howe & Co first reported a position in Charles River Laboratories in Q2 2020 and held it in 7 quarters.
Gilder Gagnon Howe & Co's Charles River Laboratories position peaked at $9.45M in Q3 2021.
644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2022, filed 16 May 2022.